filmov
tv
Sun Pharma Q4 Preview: Strong Growth In Specialty Biz Likely To Boost Q4 Performance | CNBC TV18
Показать описание
#4QWithCNBCTV18 | @SunPharma_Live to report #Q4FY23 earnings today. Growth to be driven by speciality biz while margin estimate is in the range of 24-26%. @ekta_batra lines up the expectations
Sun Pharmaceutical Industries is likely to post strong growth numbers for the quarter ended March 2023, largely driven by its specialty business, and robust sales in the domestic market. Some contribution from the sales of the generic of Revlimid, a drug used to treat multiple myeloma, in the US market will also aid growth.
#sunpharma #Q4FY23results #Q4FY23earnings #cnbctv18 #businessnews #businessnewstoday #businessnewsinenglish #sharemarkettodaynews
About CNBC-TV18: India's leading business news channel, CNBC-TV18 offers the most comprehensive coverage of businesses, the economy and the financial markets. Catch all your favourite shows, exclusive videos, big-ticket interviews and more here.
You can also connect with CNBC-TV18 News Online
n18oc_business
Sun Pharmaceutical Industries is likely to post strong growth numbers for the quarter ended March 2023, largely driven by its specialty business, and robust sales in the domestic market. Some contribution from the sales of the generic of Revlimid, a drug used to treat multiple myeloma, in the US market will also aid growth.
#sunpharma #Q4FY23results #Q4FY23earnings #cnbctv18 #businessnews #businessnewstoday #businessnewsinenglish #sharemarkettodaynews
About CNBC-TV18: India's leading business news channel, CNBC-TV18 offers the most comprehensive coverage of businesses, the economy and the financial markets. Catch all your favourite shows, exclusive videos, big-ticket interviews and more here.
You can also connect with CNBC-TV18 News Online
n18oc_business
0:01:47
0:01:14
0:00:39
0:07:48
0:05:25
0:00:55
0:10:07
0:06:49
0:06:39
0:28:10
0:00:51
0:05:00
0:03:36
0:01:12
0:01:44
0:01:02
0:00:24
0:04:20
0:15:31
0:05:31
0:00:54
1:10:15
0:00:16
0:27:00